key: cord-0261944-msfulm2q authors: Chemaitelly, H.; AlMukdad, S.; Joy, J. P.; Ayoub, H. H.; YASSINE, H. M.; Benslimane, F.; Al Khatib, H. A.; Tang, P.; Hasan, M. R.; Coyle, P.; Al Kanaani, Z.; Al Kuwari, E.; Jeremijenko, A.; Kaleeckal, A. H.; Latif, A. N.; Shaik, R. M.; Abdul Rahim, H. F.; Nasrallah, G.; Al Kuwari, M. G.; Butt, A. A.; Al Romaihi, H. E.; Al-Thani, M. H.; Alkadi, M. M.; Ali, O.; Al-Maslamani, M.; Bertollini, R.; Al Malki, H.; Almaslamani, Y.; Abu-Raddad, L. J.; Al Khal, A. title: SARS-CoV-2 vaccine effectiveness in immunosuppressed kidney transplant recipients date: 2021-08-09 journal: nan DOI: 10.1101/2021.08.07.21261578 sha: 35d0b6eaea77ea61029b8f3732d5cc19cf3a7b66 doc_id: 261944 cord_uid: msfulm2q COVID-19 vaccine protection against infection in immunosuppressed solid organ transplant recipients is unknown but possibly weak with the low proportion of these patients mounting a robust humoral and cellular immune response after vaccination. Using a retrospective cohort study design with cross-over, we assessed vaccine effectiveness among 782 kidney transplant recipients registered at Hamad Medical Corporation, the national public healthcare provider in Qatar, where the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines have been used in the national immunization campaign. Vaccine effectiveness against any SARS-CoV-2 infection was estimated at 46.6% (95% CI: 0.0-73.7%) [≥]14 days after the second dose, 66.0% (95% CI: 21.3-85.3%) [≥]42 days after the second dose, and 73.9% (95% CI: 33.0-89.9%) [≥]56 days after the second dose. Vaccine effectiveness against any severe, critical, or fatal COVID-19 disease was estimated at 72.3% (95% CI: 0.0-90.9%) [≥]14 days after the second dose, 85.0% (95% CI: 35.7-96.5%) [≥]42 days after the second dose, and 83.8% (95% CI: 31.3-96.2%) [≥]56 days after the second dose. Most vaccine breakthrough infections occurred in the first few weeks after receiving the first and/or second dose. Vaccine effectiveness reached considerable levels in kidney transplant recipients, but vaccine protection mounted slowly and did not reach a high level until several weeks after the second dose. Coronavirus Disease 2019 (COVID- 19) vaccine protection against infection in the immunosuppressed solid organ transplant recipients is unknown but suspected to be weak. 1, 2 Evidence indicates low proportion of these patients mounting a robust humoral and cellular immune response after vaccination. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] In this investigation, we assessed vaccine effectiveness in immunosuppressed kidney transplant recipients in Qatar, where the BNT162b2 19 (Pfizer-BioNTech) and mRNA-1273 20 (Moderna) vaccines have been the vaccines of choice in the national immunization campaign. [21] [22] [23] [24] We analyzed the kidney transplant database and the national federated Qatar severe acute (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.07.21261578 doi: medRxiv preprint universal healthcare system number) and Qatar Identification Number in the national centralized SARS-CoV-2 databases. We performed a retrospective cohort study with a cross-over design to estimate, for kidney transplant recipients, effectiveness of vaccination against SARS-CoV-2 infection as a primary outcome. The study compared incidence of infection in vaccinated persons and those unvaccinated between February 1-July 21, 2021, at a time when the country was undergoing two back-to-back SARS-CoV-2 waves dominated by the B.1.1.7 (Alpha 27 ) and B.1.351 (Beta 27 ) variants. 21, 23, [28] [29] [30] It is noteworthy that the first SARS-CoV-2 epidemic wave in Qatar occurred (before introduction of any variant of concern) and peaked in late May, 2020. 31,32 The second wave was triggered by introduction and expansion of the B.1.1.7 variant and peaked in early March, 2021. 21, 23, 28, 29 The third wave was dominated by the B.1.351 variant, and peaked in the first week of April, 2021. 21, 23, 28, 29 The B.1.617.2 (Delta 27 ) variant has been introduced more recently in Qatar, and as of July 28, 2021, it remains at low incidence. 28, 29 There is no evidence that any other variant of concern is or has been responsible for appreciable community transmission in Qatar. 28, 29 Individuals in the cohort of kidney transplant recipients were eligible for inclusion in the analysis if they had no prior PCR-confirmed diagnosis and were alive at the start of the follow-up time. The time of follow up was from February 1 up to July 21, 2021. Individuals were followed from February 1, 2021 until documented (PCR-confirmed) infection, death, vaccination (for those unvaccinated), or end-of-study censoring (set at July 21, 2021). Reporting of the study followed the STROBE guidelines (Supplementary Table 1 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.07.21261578 doi: medRxiv preprint Descriptive statistical analysis (frequencies and measures of central tendency) was performed to describe vaccinated and unvaccinated cohorts. Covariate differences between cohorts were evaluated using t-tests for continuous variables and chi-square tests for categorical variables, with two-sided p-value<0.05 indicating a statistically significant association. Infection hazard ratios and associated 95% confidence interval (CIs) were estimated using regressions applying the Fine-Gray model, 33 with adjustment for age, sex, and nationality group, to control for differences in exposure risk 31,32,34-37 and variant exposure 21,28,29 by sex, age, and nationality. This was done using the STATA 17.0 38 stcrreg command to account further for potential bias arising from the competing risks of vaccination and death, 33 as the duration of follow up coincided with the rapid scale-up of vaccination in Qatar. Hazard ratios were subsequently used to derive vaccine effectiveness and its 95% CI using the equation, 1-hazard ratio. The 95% CIs were not adjusted for multiplicity. Interactions were not considered. Adjusted curves for cumulative incidence were generated using the stcurve command, which fits a Fine-Gray model, 33 with adjustment for age, sex, and nationality group, to account for potential bias arising from the competing risks of vaccination and death. In addition to the baseline analysis comparing incidence of documented infection in individuals who completed ≥14 days after the second vaccine dose to that in the cohort of individuals with no vaccination record, two subgroup analyses were performed contrasting incidence in individuals who completed ≥42 days and ≥56 days after the second vaccine dose with that in the unvaccinated cohort. In all analyses, nationality was categorized into: Bangladeshis, Indians, Nepalese, Pakistanis, and Sri Lankans (Group 1), Qataris (Group 2), and all other nationalities (Group 3). This categorization was informed by the observed epidemiology and exposure risk assessments of All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The study was approved by the Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards with waiver of informed consent. Incidence of documented SARS-CoV-2 infection, symptomatic or asymptomatic, was assessed in all immunosuppressed kidney transplant recipients (n=782) registered and clinically followed at Hamad Medical Corporation, the national public healthcare provider in Qatar ( Figure 1 ). Maintenance immune suppression regimens included azathioprine (9.6%), cyclosporine (16.4%), everolimus (0.2%), mycophenolate mofetil (76.1%), prednisolone (82.5%), sirolimus (4.2%), and tacrolimus (72.9%). Out of the 782 transplant recipients, 601 (76.9%) received at least one vaccine dose by the end of the study on July 21, 2021, of whom 559 (93.0%) were vaccinated with BNT162b2 and 42 (7.0%) with mRNA-1273. The median date of first vaccine dose was All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.07.21261578 doi: medRxiv preprint February 2, 2021; and 48.3% of individuals received one or both vaccine doses before start of follow-up on February 1, 2021. Individuals in this cohort were followed from February 1, 2021 until documented (PCRconfirmed) infection, all-cause death, vaccination (for those unvaccinated), or end-of-study censoring (set at July 21, 2021; Figure 1 ). Individuals with a prior SARS-CoV-2 PCR-confirmed diagnosis (n=71), or those who died before start of follow-up (n=6), were excluded from analysis. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.07.21261578 doi: medRxiv preprint The hazard ratio adjusted for age, sex, nationality group, and the competing risks of vaccination and death was 0.53 (95% CI: 0.26-1.08). Vaccine effectiveness against any SARS-CoV-2 infection, symptomatic or asymptomatic, was derived using the equation, 1-hazard ratio, and was estimated at 46.6% (95% CI: 0.0-73.7%). Vaccine effectiveness against any severe, critical, or fatal COVID-19 disease was estimated at 72.3% (95% CI: 0.0-90.9%). Analyses were repeated to estimate vaccine effectiveness at ≥42 days and at ≥56 days after the second dose, instead of at ≥14 days after the second dose. Figures 3 and 4 show the cumulative incidence of infection including only the cohorts of individuals who completed ≥42 days and ≥56 days after the second vaccine dose, respectively, compared to that in the cohort of individuals with no vaccination record, adjusting for age, sex, nationality group, and the competing risks of vaccination and death. Cumulative incidence was assessed, respectively, at 1.60% (95% CI: 0.72-3.15%) and 1.19% (95% CI: 0.45-2.63%) among those vaccinated, versus 4.74% (95% CI: 3.00-7.07%) among those unvaccinated, after 120 days of follow-up. Vaccine effectiveness against any SARS-CoV-2 infection, symptomatic or asymptomatic, was All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Vaccine effectiveness reached considerable levels in immunosuppressed kidney transplant recipients, which were not far below those in the general population of Qatar. [21] [22] [23] [24] However, vaccine protection mounted slowly and did not reach a high level until several weeks after the second dose. Notably, the build-up of vaccine protection mirrored the slow development of antibodies in transplant recipients that has been previously reported. 3, [5] [6] [7] [8] [9] [11] [12] [13] [14] 16 Indeed, the majority of breakthrough infections in those vaccinated occurred in the first few weeks after receiving the first and/or second dose (note Figure 1 and events of infection among those vaccinated in Figure 2 ). Strikingly, no breakthrough infection was recorded in those who were already fully vaccinated before February 1, 2021, the start day of follow-up in this study (Cohort B-I in Figure 1 ). Vaccine effectiveness appeared stronger against hospitalization and death than against infection, a finding consistent with the pattern seen in the general population. 21 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.07.21261578 doi: medRxiv preprint This study has limitations. With the relatively small cohort of transplant recipients (n=782), and the rapid scale-up of vaccination during the study duration, it was not possible to match vaccinated and unvaccinated persons by factors such as age, sex, nationality, comorbidity, and calendar time, while maintaining adequate sample sizes, time of follow-up, and statistical precision. However, cohorts of both vaccinated and unvaccinated were largely balanced by both demographic and clinical characteristics (Table 1) . Moreover, the regression analyses adjusted for age, sex, and nationality group, with age being a proxy for comorbidity, and both the adjusted and unadjusted analyses reached similar results (not shown). Additionally, the majority of individuals in both vaccinated and unvaccinated cohorts were followed during similar times, starting from the first day of the study, February 1, 2021, or shortly thereafter, even in the additional analyses of vaccine effectiveness for those at ≥42 days and at ≥56 days after the second vaccine dose. Please note follow up times (results and Figure 1 ) and numbers at risk (Figures 2-4) . We only assessed risk of documented infection, but other infections may have occurred and gone undocumented, perhaps because of minimal/mild or no symptoms. Unlike in blinded, randomized clinical trials, the investigated observational cohorts were not blinded nor randomized. Vaccine effectiveness estimates calculated in this study may not necessarily be generalizable to other solid organ transplant populations. In conclusion, despite these limitations, the findings of this study demonstrate build-up of vaccine-induced protection in kidney transplant recipients, against both SARS-CoV-2 infection and COVID-19 disease, but this protection mounts slowly and does not reach a high level until several weeks after the second vaccine dose. While the present findings indicate that even immunosuppressed individuals benefit from vaccination, they suggest the need to develop better All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.07.21261578 doi: medRxiv preprint strategies to enhance the protection in this group, such as exploring the addition of a third vaccine dose. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. HC designed the study, performed the statistical analyses, and co-wrote the first draft of the article. LJA co-conceived and co-designed the study, led the statistical analyses, and co-wrote the first draft of the article. AAK co-conceived and co-designed the study. AAK, YA, HAM, OA, MMA, and JPJ constructed and populated the database of kidney transplant recipients. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, literature reviews, and to the writing of the manuscript. All authors have read and approved the final manuscript. Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise, we declare no competing interests. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.07.21261578 doi: medRxiv preprint February 1 or the organ transplant date (which ever came first) for the cohort of unvaccinated individuals, and from 14 days after the second vaccine dose for the cohort of vaccinated individuals, both up to July 21, 2021. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.07.21261578 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.07.21261578 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.07.21261578 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.07.21261578 doi: medRxiv preprint Nasopharyngeal and/or oropharyngeal swabs (Huachenyang Technology, China) were collected for PCR testing and placed in Universal Transport Medium (UTM). Aliquots of UTM were: extracted on a QIAsymphony platform (QIAGEN, USA) and tested with RT-qPCR using TaqPath™ COVID-19 Combo Kits (100% sensitivity and specificity; 1 Thermo Fisher Scientific, USA) on an ABI 7500 FAST (ThermoFisher, USA); extracted using a custom protocol 2 on a Hamilton Microlab STAR (Hamilton, USA) and tested using AccuPower SARS-CoV-2 Real-Time RT-PCR Kits (100% sensitivity and specificity; 3 Bioneer, Korea) on an ABI 7500 FAST; or loaded directly into a Roche cobas® 6800 system and assayed with a cobas® SARS-CoV-2 Test (95% sensitivity, 100% specificity; 4 Roche, Switzerland). The first assay targets the viral S, N, and ORF1ab regions. The second targets the viral RdRp and E-gene regions, and the third targets the ORF1ab and E-gene regions. All tests were conducted at the HMC Central Laboratory or Sidra Medicine Laboratory, following standardized protocols. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 1 Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 7-8 (b) Describe any methods used to examine subgroups and interactions 7 (c) Explain how missing data were addressed NA, see p. 5 (d) If applicable, explain how loss to follow-up was addressed NA, see p. 5 (e) Describe any sensitivity analyses 7 Results Participants 13* (a) Report numbers of individuals at each stage of study-eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 8 & Figure 1 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 9, 2021. ; https://doi.org/10.1101/2021.08.07.21261578 doi: medRxiv preprint Coronavirus disease 2019 vaccination in transplant recipients The impact of COVID-19 on kidney transplantation and the kidney transplant recipient -One year into the pandemic Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. medRxiv Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3-5 months followup. medRxiv Vaccine serologic responses among transplant patients associate with COVID-19 infection and T peripheral helper cells. medRxiv Comparison of humoral and cellular responses in kidney transplant recipients receiving BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines. medRxiv Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar. JAMA. 2021. 25. World Health Organization. COVID-19 clinical management: living guidance National Project of Surveillance for Variants of Concern and Viral Genome Sequencing. Qatar viral genome sequencing data One year of SARS-CoV-2: Genomic characterization of COVID-19 outbreak in Qatar. medRxiv Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar Supplementary Text 2. COVID-19 severity, criticality, and fatality classification and/or signs of severe respiratory distress (accessory muscle use and inability to complete full sentences, and, in children, very severe chest wall indrawing, grunting, central cyanosis, or presence of any other general danger signs)". 5 Detailed WHO criteria for classifying SARS-CoV-2 infection severity can be found in the WHO technical report Critical COVID-19 disease was defined per WHO classification as a SARS-CoV-2 infected person with "acute respiratory distress syndrome, sepsis, septic shock No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. References 1. Thermo Fisher Scientific. TaqPath™ COVID-19 CE-IVD RT-PCR Kit instructions for use High-throughput extraction of SARS-CoV-2 RNA from nasopharyngeal swabs using solid-phase reverse immobilization beads Molecular and Serological Tests for COVID-19 a Comparative Review of SARS-CoV-2 Coronavirus Laboratory and Point-of-Care Diagnostics. Diagnostics (Basel) Cobas® SARS-CoV-2: Qualitative assay for use on the cobas® 6800/8800 Systems World Health Organization. COVID-19 clinical management: living guidance International guidelines for certification and classification (coding) of COVID-19 as cause of death